- Raised funding round, Jul 2024
About
ProPhet is an AI-driven company transforming small molecule drug discovery, with a focus on proteins that are hard to target using competitive methods. The company develops advanced technology to identify potential therapeutics for these challenging targets, addressing a critical need in the pharmaceutical industry.
Its innovative approach leverages artificial intelligence and machine learning to speed up and enhance the early stages of drug discovery. By predicting protein dynamics and how they interact with drug candidates, ProPhet can rapidly identify promising molecules. This allows to tackle proteins with limited structural information, opening new possibilities for treating diseases previously considered “undruggable.”
ProPhet stands out by combining speed, precision, and scientific rigor. Its AI platform evaluates vast libraries of small molecules, offering faster, more efficient, and cost-effective solutions compared to both traditional and other AI-based methods. By doing so, it helps pharmaceutical companies and researchers explore a broader range of treatments with more accuracy, backed by scientifically interpretable results.
Its vision is to revolutionize drug discovery, making it faster and more accessible. ProPhet aims to deliver better solutions to help meet unmet medical needs and improve patient outcomes.
Funding history · 1 round · $1.0M total
Q&A
- What is ProPhet's primary focus?
- ProPhet is an AI-driven company focused on transforming small molecule drug discovery, specifically targeting proteins that are difficult to address with competitive methods.
- When was ProPhet founded?
- ProPhet was founded in July 2024.
- Where is ProPhet headquartered?
- ProPhet is headquartered in Rehovot, Center District, Israel.
- What is ProPhet's current funding stage?
- ProPhet is currently in the Pre-Seed funding stage.
- Which investors participated in ProPhet's July 2024 funding round?
- In July 2024, ProPhet received investment from Merck and AION Labs.
- What technologies does ProPhet leverage in its drug discovery process?
- ProPhet leverages Artificial Intelligence, Deep Learning, and Machine Learning in its drug discovery process.
- Who are the co-founders of ProPhet?
- The co-founders of ProPhet are Tom Shani (CEO), Avital Sharir-Ivry (CSO), and Amitai Mordechai (CTO).
Team · 3
Sectors & technology
Highlights
Tags
Full data — links, identifiers, deals & radar signals (jobs, patents, research, more)
External links
| Website | pro-phet.com/ |
|---|---|
| linkedin.com/company/105102824 |
Identifiers & details
| Founded | 2024-7 |
|---|---|
| Employees (exact) | 8 |
Radar intelligence
Open jobs — greenhouse
| Total open | 19 |
|---|---|
| Remote | 0 |
| By department | Corporate (4), Strategy (4), Digital (3), Design (6), Digital Experience & Campaigns (2) |
| By location | Austin (2), Hong Kong, (1), Zurich (1), New York (2), Chicago (1), Austin, TX (1), London (3), New York, Chicago (2), New York, New York, United States, Richmond, Virginia, United States (1), New York, New York (2), New York, NY (1), New York, NY (1) |
| Title | Location | Department |
|---|---|---|
| Executive Assistant/Office Manager | Austin | Corporate |
| Associate Intern | Hong Kong, | Strategy |
| Associate - Zurich | Zurich | Strategy |
| Talent Acquisition Intern | New York | Corporate |
| Senior Product Manager — AI Foundry Team | New York | Digital |
| Insights Associate | Chicago | Strategy |
| Insights Associate | Austin | Strategy |
| Resource Coordinator | Austin, TX | Corporate |
| Design Intern | London | Design |
| Senior Associate, AI Foundry & Digital Growth | New York, Chicago | Digital |
| Associate, AI Foundry & Digital Growth | New York, Chicago | Digital |
| Business Development Senior Associate | New York, New York, United States, Richmond, Virginia, United States | Corporate |
Patents
| EPO | 125 |
|---|
Publications (Crossref)
| Works | 10 |
|---|